Adalimumab (tumor necrosis factor-blocker) reduces the expression of glial fibrillary acidic protein immunoreactivity increased by exogenous tumor necrosis factor alpha in an organ...

por Fernandez-Bueno, I., Garcia-Gutierrez, M.T., Srivastava, G.K., Gayoso, M.J., Gonzalo-Orden, J.M., Pastor, J.C.
Publicado 2013